^
    5d
    AK104-310: A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma (clinicaltrials.gov)
    P3, N=760, Recruiting, Akeso | Not yet recruiting --> Recruiting
    Enrollment open
    |
    oxaliplatin • Kaitanni (cadonilimab) • Teysuno (gimeracil/oteracil/tegafur)
    6d
    Comparative Cost-Effectiveness Analysis of Multiple First-Line Treatments for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer in Japan. (PubMed, Pharmacoecon Open)
    At a willingness-to-pay threshold of USD 100,000/QALY (Japan's HTA upper reference), SOX was identified as the most cost-effective first-line treatment for HER2-negative unresectable advanced or recurrent GC in Japan.
    Journal • HEOR • Cost-effectiveness
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab-clzb) • Teysuno (gimeracil/oteracil/tegafur) • levoleucovorin calcium
    13d
    SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    paclitaxel • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • retlirafusp alfa (SHR-1701)
    16d
    Safety,efficacy and mechanisms of envolimab and S-1 systemic therapy combined with intraperitoneal endostar in the treatment of gastric/gastric-oesophageal junction adenocarcinoma with malignant ascites in elderly patients over 70 years. (ChiCTR2500115706)
    P=N/A, N=30, Recruiting, Beijing Hospital; Beijing Hospital
    New trial
    |
    Teysuno (gimeracil/oteracil/tegafur) • Endostar (recombinant human endostatin)
    16d
    Sintilimab Plus Systemic Chemotherapy With or Without Intraperitoneal Nab-Paclitaxel for Treatment-Naïve HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: A Phase III Randomized Controlled Trial (ChiCTR2600117422)
    P3, N=344, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-Sen University Cancer Center
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    Tyvyt (sintilimab) • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)
    16d
    A prospective, single-center, exploratory phase II clinical study of QL1706 combined with chemotherapy in the treatment of previously untreated advanced or metastatic gastric cancer or gastroesophageal junction cancer. (ChiCTR2600116087)
    P2, N=32, Not yet recruiting, Beijing Friendship Hospital, Capital Medical University; Beijing Friendship Hospital, Capital Medical University
    New P2 trial
    |
    HER-2 overexpression • HER-2 amplification
    |
    oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • Qibeian (iparomlimab/tuvonralimab)
    16d
    Disitamab Vedotin and Adebrelimab in combination with SOX in the perioperative treatment of HER2-expressing Locally Advanced Esophageal Adenocarcinoma and Esophagogastric Junction Adenocarcinoma: A Prospective, Single-Arm Phase II Study (ChiCTR2500115516)
    P2, N=39, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    oxaliplatin • Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)
    16d
    Liposomal Irinotecan Plus 5-FU/LV Compared with Sequential Alternating nab-Paclitaxel Plus S-1 as Second-Line Therapy in Patients with Advanced Biliary Tract Cancer: A Randomized, Open-Label, Prospective Trial (ChiCTR2500111686)
    P2, N=58, Not yet recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
    New P2 trial
    |
    5-fluorouracil • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)
    16d
    Prospective Study With HIPEC and AS regimen plus PD-L1 antibody with Fruquintinib in Patients With Peritoneal Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (ChiCTR2500113398)
    P2, N=52, Not yet recruiting, Zhongshan Hospital Fudan University; Zhongshan Hospital Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    albumin-bound paclitaxel • Fruzaqla (fruquintinib) • Teysuno (gimeracil/oteracil/tegafur)
    18d
    Intraperitoneal Paclitaxel-Induced Eosinophil Recruitment as a Potential Mediator of Tumor Response in Peritoneal Metastases from Gastric Cancer. (PubMed, Ann Surg Oncol)
    IP PTX promotes the recruitment and activation of eosinophils with potent antitumor activity in the peritoneal cavity. Early post-treatment abdominal eosinophilia is a robust prognostic biomarker and may represent a promising therapeutic target to enhance the efficacy of IP chemotherapy in patients with PM from GC.
    Journal
    |
    CD4 (CD4 Molecule) • ITGAM (Integrin, alpha M) • CCR3 (C-C Motif Chemokine Receptor 3) • CEACAM8 (CEA Cell Adhesion Molecule 8)
    |
    paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    19d
    Huaxi: Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma (clinicaltrials.gov)
    P2, N=154, Not yet recruiting, Sichuan University
    New P2 trial
    |
    oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • Yidafan (ivonescimab)
    19d
    MA-GC-II-019: Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer (clinicaltrials.gov)
    P2, N=80, Active, not recruiting, Ruijin Hospital | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)